Skip to content
ApprovedFDA approvedLimited evidence

Vorinostat

Prescription anticancer drug approved for a skin lymphoma; its nerve-protecting effect has only been seen in animal studies.

NootropicHDAC InhibitorHDAC InhibitorNeuroprotectionnoo.affects.gene-expressionnoo.affects.hdacnoo.affects.neuroprotection

Pharmacology

ClassHDAC Inhibitor · Neuroprotection
Primary targetHistone deacetylase (HDAC) pan-inhibitor
Targets3 receptor targets
Half-lifeApproximately 2 hours
OnsetDosed once daily with food in clinical use
EvidenceLimited evidence
Affected systemsnoo.affects.gene-expressionnoo.affects.hdacnoo.affects.neuroprotection

Contents

DETAILED OVERVIEW

What is Vorinostat?

Vorinostat (SAHA) is a prescription anticancer drug that was approved in the United States in 2006 under the name Zolinza for a certain skin lymphoma (cutaneous T-cell lymphoma); it is not approved in the European Union. It is not a dietary supplement and not a nootropic: its use for memory or nerve protection is purely experimental and possible only under medical supervision.

It blocks enzymes that control how readable genes are; in tumor cells this stops cell division and triggers programmed cell death. In rodents the same effect reversed learning and memory problems caused by stress or anesthesia, but in humans a nerve-protecting benefit has never been shown, and it enters the brain poorly. As a cancer drug it has serious side effects, for example nausea, diarrhea, a drop in platelets and blood cells, blood clots (for example pulmonary embolism) and a disturbance of the heart's electrical activity (QT prolongation). It must not be used in pregnancy because it can harm the fetus.

Mechanism

Broad histone deacetylase inhibitor; binds the enzyme's zinc

Half-life

Approximately 2 hours

Legal status

FDA-approved prescription cancer drug

Receptor profile

  • Histone deacetylase (HDAC) enzymesStrong
  • Gene transcription / chromatin remodelingStrong
  • Memory and neuroprotection (research)Weak

Safety

Side effects, stop signs, contraindications

Side effects · 6

  • Fatigue, nausea, diarrhea (common at clinical oncology doses)
  • Reduced platelet and blood cell counts (thrombocytopenia, anemia)
  • Increased tendency to blood clots (risk of pulmonary embolism and deep vein thrombosis)
  • Fluctuating blood glucose (hyperglycemia)
  • Prolongation of cardiac electrical conduction (QT prolongation)
  • Dehydration, loss of appetite, taste disturbance

Contraindications · 5

  • Pregnancy and breastfeeding: teratogenic and fetotoxic, strictly avoid
  • History of thromboembolism (deep vein thrombosis, pulmonary embolism): increased clot risk
  • QT prolongation or concurrent QT-prolonging drugs: arrhythmia risk
  • Bone marrow suppression or low platelet count: requires regular blood-count monitoring
  • Prescription oncology drug, only under medical supervision; not for self-medication

Related Nootropics

Same therapeutic category

Studies

Related research and clinical findings

FAQ

FAQ

Vorinostat is an FDA-approved cancer drug (used for a specific type of skin lymphoma), and its brain-protective, memory-boosting effect has so far only been observed in animal studies. In rodent models it improved learning and memory problems caused by stress, insulin resistance, or anesthesia by changing how certain genes are read out, but using it for cognitive purposes in humans is not an approved use, it remains purely research/experimental at this stage.

Telegram

Have a question about Vorinostat?

Reach out to us on Telegram for a personalized stack. We'll be happy to help.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

Structure & chemistry

TypeNootropic
FormulaC14H20N2O3
UpdatedOctober 14, 2026
MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.